Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

JPMorgan Slashes Monte Rosa Therapeutics Target Price by Nearly One-Fifth

Guavy AI Editorial Team
Instruments
JPM
Share

JPMorgan Chase & Co., one of the top investment banks, has lowered its target price for Monte Rosa Therapeutics (NASDAQ: GLUE) from $31.00 to $27.00 in a report issued on Friday.

The firm presently has an 'overweight' rating on the stock and suggests a potential upside of 68.70% from the company's current price, which is at $16.00.

This move comes after several other investment banks have also revised their target prices for Monte Rosa Therapeutics in recent weeks.

More on Stocks

Stocks 2m ago

Amgen's Volatility Zones Spark Trader Interest Amid Strong Sentiment

Stocks 7m ago

Insurers Surpass Expectations as Healthcare Costs Manage Q2

Stocks 9m ago

Honeywell International Share Price Plunges Amid Aerospace Spin-Off Woes

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy